drugset / Trial / NCT06684197

The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption

NCT06684197 ↗

Not yet recruiting 72 enrolled Ciusss de L'Est de l'Île de Montréal
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Opioids analgesic are the gold standard for intraoperative pain management. Their short- and long-term adverse effect motivate anesthesiologists to explore opioid sparing strategies. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. This new randomized controlled trial (RCT) will answer the question whether an intraoperative dexmedetomidine infusion compared to placebo has a clinically significant impact on intraoperative remifentanil consumption during a laparoscopic abdominal elective surgery.

Timeline

Start
2024-11
Primary completion
2025-11
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous

Indications

No indication recorded.